The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial
Open accessAbstract
BACKGROUND AND AIMS: NAFLD is characterized by insulin resistance and dysregulated lipid and glucose metabolism. Saroglitazar, a dual peroxisome proliferator activated receptor-α/γ agonist, improves insulin sensitivity, and lipid and glycemic parameters. Saroglitazar improved NASH histology in animal studies. In this randomized controlled clinical trial, we evaluated the efficacy and safety of saroglitazar in patients with NAFLD/NASH. APPROACH AND RESULTS: were randomized in a 1:1:1:1 ratio to receive placebo or saroglitazar 1 mg, 2 mg, or 4 mg for 16 weeks. The primary efficacy endpoint was percentage change from baseline in ALT levels at week 16. Liver fat content (LFC) was assessed by MRI proton density fat fraction. The least-squares mean percent change from baseline in ALT at week 16 was -25.5% (5.8), -27.7% (5.9), and -45.8% (5.7), with saroglitazar 1 mg, 2 mg, and 4 mg, respectively, versus 3.4% (5.6) in placebo (P < 0.001 for all). Compared with placebo, saroglitazar 4 mg improved LFC (4.1% [5.9] vs. -19.7% [5.6]), adiponectin (-0.3 μg/mL [0.3] vs. 1.3 μg/mL [0.3]), homeostatic model assessment-insulin resistance (-1.3 [1.8] vs. -6.3 [1.7]), and triglycerides (-5.3 mg/dL [10.7] vs. -68.7 mg/dL [10.3]) (P < 0.05 for all). Saroglitazar 4 mg also improved lipoprotein particle composition and size and reduced lipotoxic lipid species. Saroglitazar was well-tolerated. A mean weight gain of 1.5 kg was observed with saroglitazar 4 mg versus 0.3 kg with placebo (P = 0.27). CONCLUSIONS: Saroglitazar 4 mg significantly improved ALT, LFC, insulin resistance, and atherogenic dyslipidemia in participants with NAFLD/NASH. (ClinicalTrials.gov identifier: NCT03061721.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Two Phase II trials have investigated the effects of saroglitazar, a PPARα/γ agonist, and found improvement of ALT and hepatic fat (measured via MRI‐PDFF) [57] but no improvement of NAS (primary endpoint: delta change of NAS from baseline to Week 24 biopsy) [58].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [57]
The cited source says what the claim attributes to it.
In the citing paper
“Saroglitazar, a dual PPAR a / c agonist has been shown to improve insulin resistance, liver steatosis and liver enzymes 426 and is approved in India for the treatment of T2D and MASH.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [426]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This lack of basic information may have confounded true treatment effects and results in serious difficulties concerning cross-trial comparisons [240].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [240]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citation2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationVernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
Association of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli‐Labate, A. M., Bianchi, G. P., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,570
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2010) · Annals of Medicine · doi:10.3109/07853890.2010.518623 · Cited by 1,304
Flagged first, then by citations
1 of the 48 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 379
Yagai, T., & Nakamura, T. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1060244 · Cited by 10
Ji, X., Ma, Q., Wang, X., Ming, H., Bao, G., Fu, M., & Wei, C. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116827 · Cited by 10
Zhang, R., Gao, C., Hu, M., Wang, X., Li, S., An, Z., Yang, X., & Xie, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1336232 · Cited by 9
Application of PPAR Ligands and Nanoparticle Technology in Metabolic Steatohepatitis Treatment
Vu, H. T., Nguyen, V. D., Ikenaga, H., & Matsubara, T. (2024) · Biomedicines · doi:10.3390/biomedicines12081876 · Cited by 9
Cazac, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041042 · Cited by 10
Xiao, Q., Wang, C., Yang, H. J., Gao, X., Chen, Z., Niu, Z., Hou, Y., Fu, C., Yan, Z., Zhu, G., et al. (2025) · Nano Letters · doi:10.1021/acs.nanolett.5c04561 · Cited by 9
Das, S., Agarwal, K., Kapoor, N., Lakhani, O., & Gupta, A. D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000935 · Cited by 10
Liu, J., Yang, F., Gao, B., Yang, L., Cao, Y., & Zhou, Y. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01574-w · Cited by 11
Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities
Александровна, П. В., & Okovityi, S. V. (2026) · Biomedicines · doi:10.3390/biomedicines14040909 · Cited by 10
Tai, Y., Zhao, C., Lan, T., Zhang, L., Xiao, Y., Tong, H., Liu, R., Tang, C., & Gao, J. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.706341 · Cited by 9
NAFLDkb: A Knowledge Base and Platform for Drug Development against Nonalcoholic Fatty Liver Disease
Xu, T., Gao, W., Zhu, L., Chen, W., Niu, C., Yin, W., Ma, L., Zhu, X., Ling, Y., Gao, S., et al. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00395 · Cited by 11
Roy, A., Tewari, B., Giri, S., & Goenka, M. K. (2023) · Cureus · doi:10.7759/cureus.47493 · Cited by 9
Sun, Y., Shen, Y., Liang, X., Zheng, H., & Zhang, Y. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.02.001 · Cited by 12
Inhibition of mGluR5 ameliorates lipid accumulation and inflammation in HepG2 cells
Zeng, S., Tao, M., Yuan, L., Zhang, L., & Luo, X. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.02.033 · Cited by 8
Khatoon, S., Das, N., Chattopadhyay, S., Joharapurkar, A. A., Singh, A., Patel, V. J., Nirwan, A., Kumar, A., Mugale, M. N., Mishra, D. P., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176800 · Cited by 8
Niu, Q., Xi, Y.-T., Li, Z., Zhang, C., Li, X.-Y., Li, C.-Z., Wang, H.-D., Zhang, M.-X., zhu, M., & Li, P. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177092 · Cited by 8
Sun, Q., Cui, X., Yin, D., Li, J., Li, J., & Du, L. (2025) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-025-01090-x · Cited by 8
Pathogenesis and Clinical Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
Lucaciu, R. L., Coste, S. C., Hangan, A. C., Iancu, M., Orasan, O. H., Cozma, A., Bogdan, S. G., & Procopciuc, L. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125717 · Cited by 11
Fu, M., Xie, Z., Li, Q., Jiang, J., Zhao, Z., Qiu, M., Chen, X., & Hu, J. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.114767 · Cited by 8
Kim, J., BAJAJ, H. S., Ramji, A. S., Bémeur, C., & Sebastiani, G. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.04.003 · Cited by 11
White adipose tissue browning and peroxisome proliferator activated receptors in MASLD
Li, Z., Chu, H., & Yang, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1667037 · Cited by 9
Durga, D. R., Mounika, N., Mudimala, P., & Adela, R. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01219-6 · Cited by 8
The Troubling Link Between Non-alcoholic Fatty Liver Disease (NAFLD) and Extrahepatic Cancers (EHC)
Venniyoor, A., Farsi, A. M. A., & Bahrani, B. J. A. (2021) · Cureus · doi:10.7759/cureus.17320 · Cited by 8
Tan, Y., Qu, W., Zhao, J., Ma, Y., Zhang, Q., Gao, H., Zhen, Q., Wang, Y., Peng, Y., Liu, F., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101680 · Cited by 7
Lee, B. K., Ghumman, U., Pedicone, L. D., Gómez-Aldana, A., & Lawitz, E. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0337 · Cited by 9
Yu, C., Han, D., Yu, J., Zhu, R., Zhu, C., Wang, F., & Zhang, T. (2023) · Medicine · doi:10.1097/md.0000000000035460 · Cited by 7
State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Cho, Y., & Lee, Y. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.102 · Cited by 7
Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2
Koullias, E., & Koskinas, J. S. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00564 · Cited by 7
Sugihara, T. (2025) · Yonago acta medica · doi:10.33160/yam.2025.05.002 · Cited by 8
Yu, M., Ren, X. D., Li, R., Shen, W., Zhao, B., Li, Y., Zhang, X., Cui, X., Zhu, J., Zhang, X., et al. (2025) · Molecular Pharmacology · doi:10.1016/j.molpha.2025.100065 · Cited by 6
PPARs in molecular pathogenesis and drug treatment of type 2 diabetes-related MASLD
Lonardo, A., & Weiskirchen, R. (2025) · Exploration of Digestive Diseases · doi:10.37349/edd.2025.100590 · Cited by 6
Pharmacological agents for defatting livers by normothermic machine perfusion
Li, S., Chen, L., Li, M., & Lv, G. (2022) · Artificial Organs · doi:10.1111/aor.14478 · Cited by 7
Mechanism of Action of the Plateau-Adapted Gene PPARA in COPD
Li, H., Pei, W., Wang, Y., Zhang, Y., Yang, Z. C., & Wang, X. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2902068 · Cited by 7
Research Progress of Natural Products with the Activity of Anti-nonalcoholic Steatohepatitis
Wang, R., Mao, Y., Yu, C., Rong, Z., Wang, R., Wang, Y., Lv, L., Gao, Y., Wang, Z., & Zhang, H. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575306598240503054317 · Cited by 6
Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
Katsarou, A., Tsioulos, G., Kassi, E. N., & Chatzigeorgiou, A. (2024) · HORMONES · doi:10.1007/s42000-024-00588-1 · Cited by 8
Wang, S., Li, X., Xu, W., Gao, J. X., Wang, Y., Jia, X., Li, G., Pan, Q., & Chen, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416063 · Cited by 6
GUPTA, M., Lachhwani, H., Chandra, K. P., Awasthi, R., & Kumar, D. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70144 · Cited by 5
Treating metabolic dysfunction‐associated steatohepatitis: The fat‐trimming FGF21 approach
Li, X., Rao, Z., Hu, W., Lu, W., & Luo, Y. (2024) · Obesity Reviews · doi:10.1111/obr.13861 · Cited by 6
Misceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 6
Tan, C. X. A., Li, R., Zhang, F., Dai, L., Ullah, N., & Lü, Y. (2022) · Angewandte Chemie · doi:10.1002/ange.202209494 · Cited by 5
Arnold, J., Idalsoaga, F. J., Díaz, L. A., Cabrera, D., Francisco Barrera, M., Arab, J. P., & Arrese, M. A. (2024) · Current Hepatology Reports · doi:10.1007/s11901-023-00629-0 · Cited by 5
Puri, S., Kirad, S., Muzaffar-Ur-Rehman, M., Mandal, S. K., Sharma, P. K., Murugesan, S., & Deepa, P. R. (2024) · RSC Advances · doi:10.1039/d4ra06037g · Cited by 5
Grzych, G., Bernard, L., Lestrelin, R., Tailleux, A., & Staels, B. (2022) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2022.09.005 · Cited by 5
Saroglitazar – A Potential Therapeutic Option in Treating NASH? [Letter]
Shuja, S. H., Eqbal, F., & Rehman, H. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s341223 · Cited by 5
Fu, R., Zhang, F., Fu, J., Li, Y., Zhu, X., Ding, Q., & Zhu, Y. Z. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.163 · Cited by 6
Zhang, Y., Pei, Z., Wen, Z., Chen, Y., Wang, H., Tan, W., Chen, X. Y., Liu, J., & Ni, Q. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1706384 · Cited by 5
Malandris, K., Papandreou, S., Vasilakou, D., Kakotrichi, P., Sarakapina, A., Kalopitas, G., Karagiannis, T., Γιουλεμέ, Ό., Bekiari, E., Liakos, A., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16559 · Cited by 5
Liu, Y., Yu, Z. H., Wang, X., Yuan, M., Lu, M., Gong, M., Li, Q., Xia, Y., Yang, G., Xu, B., et al. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i5.101354 · Cited by 4
Liu, Y., Chen, L., Liu, X., Tao, R. N., Dong, R., Wang, X., Luo, J., Li, H., Zheng, Y., Qiang, L., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157053 · Cited by 4
Kumar, A. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.1058 · Cited by 5
Jia, W., Wu, S., Wang, K., Wang, X., Li, J., Xu, H., & Ji, L. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157474 · Cited by 5
Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis
Abreu, E. S., Noureddin, M., Takahashi, H., Schattenberg, J. M., & Abdelmalek, M. F. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.004 · Cited by 4
Self-citationFuentes-Barría, H., Aguilera-Eguía, R. A., Alarcón-Rivera, M., Angarita, L., & Flores-Fernández, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062532 · Cited by 4
Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options
Ren, R., Liang, X., & Wei, X. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00486-5 · Cited by 5
Dutta, D., Mohindra, R., & Misra, A. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-022-01245-4 · Cited by 4
Menezes, A. D. S., Oliveira, V. M. R., Oliveira, I. C., de Sousa, A. M., Santana, A. J. P., Carvalho, D. P. C., Piai, R. F. P., Matos, F. H., de Paiva, A. M., & Reis, G. B. B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175674 · Cited by 4
Xiao, L., Liang, C., Gao, J., Wang, Y., Guo, Y., Chen, K., & Jia, X. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21973 · Cited by 4
Exploring the potential of drug repurposing for liver diseases: A comprehensive study
Ali, F. E. M., Abdel‐Reheim, M. A., Hassanein, E. H. M., El‐Aziz, M. K. A., Althagafy, H. S., & Badran, K. S. A. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122642 · Cited by 5
Metabolic-dysfunction associated steatotic liver disease (MASLD)
De, A., Panigrahi, M. K., Duseja, A. K., & Singh, S. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-26711-6.00031-7 · Cited by 5
Simental‐Mendía, L. E., Simental-Mendía, M. A., Barragán‐Zuñiga, L. J., & Arce‐Quiñones, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16506 · Cited by 4
Erukulapati, R. S., Ganguri, M., Menon, A. S., Ayyagari, U., Jayapaul, M. K., Gurazada, K. C., Nalla, S., Srinath, A., Sampath, S. K., Manohar, S. P., et al. (2023) · Clinical Diabetology · doi:10.5603/dk.a2022.0061 · Cited by 4
Yang, H., Wei, D., Zhang, Y., & Jian, W. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303257018230927182802 · Cited by 4
Afarin, R., Dinarvand, N., Asl, B. J., Orak, G., Shakerian, E., Bineshfar, F., & Ahangarpour, A. (2024) · PubMed Central · doi:10.22038/ijbms.2023.70157.15255 · Cited by 4
Francque, S. (2021) · Hepatology · doi:10.1002/hep.32024 · Cited by 4
Pediatric NASH therapies: A speedbump on the road to success
Softic, S., & Kohli, R. (2022) · Hepatology · doi:10.1002/hep.32322 · Cited by 4
Risk factors and prediction for DILI in clinical practice
Björnsson, H. K., & Bjornsson, E. S. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2468200 · Cited by 3
Xiong, Y., Luo, W., Ye, J., Cui, Y., Zheng, X., Jin, L., Lou, S., Zhang, Q., Wang, A., Fang, Y., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70161 · Cited by 3
Kaya, E., Yilmaz, Y., & Alkhouri, N. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2566258 · Cited by 5
Feng, J., Wang, X., Ji, L., Liang, X., Liangpunsakul, S., Huang, L., Zhang, X., Gao, Y., Fang, M., Yu, Z., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120760 · Cited by 3
Recent advances in the design, development and therapeutic applications of PPARγ agonists
Ghannam, I. A. Y., Abdel‐Mohsen, H. T., & Ali, I. H. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2571022 · Cited by 3
Zacharia, G. S., Ashraf, M. H., Sosa, F., Jacob, A., & Patel, H. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i4.110827 · Cited by 3
Liver Fibrosis: Molecular Pathogenesis and Therapeutic Interventions
Qu, J., Qin, W., Dong, M., Ma, Z., Li, S., Liu, R., Chen, R., Li, C. H., & Li, X. (2026) · MedComm · doi:10.1002/mco2.70750 · Cited by 3
How far are we from an approved drug for nonalcoholic steatohepatitis?
Méndez‐Sánchez, N., Pal, S. C., & Córdova‐Gallardo, J. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2206953 · Cited by 3
Wei, C., Wu, J., Zhang, C., Zhao, Y., Li, C., & Yang, X. (2023) · Exploration of Digestive Diseases · doi:10.37349/edd.2023.00031 · Cited by 3
Emerging Combination of Saroglitazar and Vitamin E for the Treatment of NAFLD and NASH
Tavaglione, F., & Loomba, R. S. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.101449 · Cited by 3
Choi, R., Vemuri, J. P., Poloju, A., Raj, R., Mehta, A., Asgharpour, A., Siddiqui, M. S., & Majety, P. (2025) · Endocrines · doi:10.3390/endocrines6020027 · Cited by 3
A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség.
Pár, A., Wittmann, I., & Pár, G. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32480 · Cited by 3
A novel therapy for hepatic cholestasis treatment—the combination of rosiglitazone and fenofibrate
Chen, Y., Yang, S., Liu, L., Yang, X., Duan, Y., Zhang, S., & Han, J. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175428 · Cited by 3
Non-alcoholic Steatohepatitis in Asians: Current Perspectives and Future Directions
Choudhuri, G., Shah, S., Kulkarni, A. V., Jagtap, N., Gaonkar, P. P., Desai, A. S., & Adhav, C. V. (2023) · Cureus · doi:10.7759/cureus.42852 · Cited by 4
Letter to the Editor: Saroglitazar for Treatment of NAFLD and NASH
Kumar, K., Kulkarni, A. V., & Jagdish, R. K. (2021) · Hepatology · doi:10.1002/hep.32094 · Cited by 3
The Perspective of PPAR Dual/Pan Agonists as Therapeutic Drugs against NAFLD
Honda, A., & Ishii, I. (2022) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.22-00159-1 · Cited by 2
New Obesity Treatment Agent: β-Caryophyllene
Peiyi, H., Zang, L., & Shuguang, Z. (2024) · Current Drug Therapy · doi:10.2174/0115748855312851240823073921 · Cited by 3
Song, X., Li, D., Sun, J., Zhang, X., Wang, L.-S., & Chen, F. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250299 · Cited by 2
Bandyopadhyay, S. K., Samajdar, S. S., Chaudhuri, S., & Das, S. (2024) · Hospital Practice · doi:10.1080/21548331.2024.2412513 · Cited by 3
Moka, M. K., Rathakrishnan, D., Sriram, D. K., & George, M. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.03.024 · Cited by 2
Zhang, Y., Lin, J., Han, X., & Chen, X. (2025) · Medicina · doi:10.3390/medicina61071157 · Cited by 2
PPARidgm shifts in the treatment of metabolic dysfunction–associated steatotic liver disease
Abushamat, L. A., & Barb, D. (2025) · Hepatology · doi:10.1097/hep.0000000000001511 · Cited by 2
Zhu, W., Chang, W., Chen, T., Li, M., Han, Z., Sun, N., Fang, W. Y., & Wang, D. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120571 · Cited by 3
Zhou, Y., Chi, J., Xu, X., Zhu, R., Wang, T., Zhang, T., Hong, D., Fu, H., Zhou, X., & Zhao, K. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.157910 · Cited by 2
Kobayashi, T., Yoneda, M., Duseja, A., Fan, J.-G., Nersesov, A., & Nakajima, A. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.010 · Cited by 3
Roles of peroxisome proliferator-activated receptors (PPARs) in pancreatic metabolic diseases
Han, X., Geng, Y., Li, Y., Meng, X., & Jiao, J. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108192 · Cited by 2
Lean metabolic dysfunction-associated steatotic liver disease: Current insights and knowledge gaps
Praveen Sandeep Raj, R., John, R., Manoharan, F., Janeela, A. M., Goel, A., & Kapoor, N. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102107 · Cited by 5
Choudhuri, B. (2026) · Case Reports in Gastroenterology · doi:10.1159/000552414 · Cited by 2
Anand, A. C., & Acharya, S. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.01.008 · Cited by 2
Bentsa, T. М. (2023) · Modern Gastroenterology · doi:10.30978/mg-2023-6-59 · Cited by 3
Mohamed Anasdeen, S., Shahinaz, S., & Vijayakumar, T. M. (2024) · Cureus · doi:10.7759/cureus.67151 · Cited by 3
Clinical Case Series on Assessment of Therapeutic Efficacy of Saroglitazar in MASLD Patients
Dang, N., & Wairokpam, T. (2024) · Asian Journal of Medicine and Health · doi:10.9734/ajmah/2024/v22i91085 · Cited by 2
Tiwari, K., Kumar, B., Tiwari, A., Dhamija, P., Vardhan, G., Dehade, A., & Kumar, V. (2025) · Cureus · doi:10.7759/cureus.79437 · Cited by 2
Design and synthesis of ERα agonists: Effectively reduce lipid accumulation
Yang, J., Yao, W., Yang, H., Shen, Y., & Zhang, Y. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.1104249 · Cited by 2
Lawitz, E., Parmar, D., Momin, T., Shaikh, F., Patel, H., Hayes, H., & Swint, K. (2023) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1339 · Cited by 2
Self-citation
Metadata
- Authors
- Gawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., Kowdley, K. V., Lai, M., Schiff, E., Parmar, D., Patel, P., & Chalasani, N.
- Affiliations
- Indiana University School of Medicine (US)
- Cedars-Sinai Medical Center (US)
- Texas Liver Institute (US)
- Catalina Research Institute (US)
- Marion General Hospital (US)
- University of Florida Health (US)
- Liver Institute Northwest (US)
- Beth Israel Deaconess Medical Center (US)
- University of Miami (US)
- Zydus Discovery DMCC,Dubai,UAE
- Zydus Lifesciences Limited (India) (IN)
- Corresponding author
- Chalasani, Naga
- ORCID
- Venue
- Hepatology
- Published
- 2021-07-19
- Volume
- 74
- Issue
- 4
- Pages
- 1809-1824
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W3149930516
- Cited by
- 379
- References
- 48
- Citations by year
- 2026: 46 · 2025: 82 · 2024: 82 · 2023: 87 · 2022: 57 · 2021: 25
- FWCI
- 45.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Celgene
- Novo Nordisk
- Allergan
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- saroglitazar, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, PPAR alpha/gamma agonist, insulin resistance, atherogenic dyslipidemia, liver fat, ALT, adiponectin, triglycerides, drug safety and tolerability, weight gain, PPARγ antagonist, PPARα
- MeSH terms
- Adipose Tissue, Adult, Alanine Transaminase, Alkaline Phosphatase, Aspartate Aminotransferases, Cholesterol, Double-Blind Method, Female, gamma-Glutamyltransferase, Humans, Insulin Resistance, Cholesterol, HDL, Cholesterol, LDL, Liver, Magnetic Resonance Imaging, Male, Middle Aged, Phenylpropionates, Pyrroles, Triglycerides, Cholesterol, VLDL, PPAR alpha, PPAR gamma, Elasticity Imaging Techniques, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
